Register Now! Early Bird Savings End In:
- 00Days
- 00Hrs
- 00Mins
- 00Secs
End to end case study of successful certification
Technical file preparation and submission
Notified body review
Common questions, pain points and lessons
- Harmonization of CTA and PSA
- Timing of therapeutic product and CDx approval/co-approval- Oncology and Beyond
- Use of in-house testing exemption to support CDx as needed
- Product Labeling- SmPC and SSP
- Intended purpose/off-label use
- Changes to a CDx Device and Communication with HA
Following on from yesterday’s morning session, our experts take the time to answer your most asked questions, comments and concerns, as well as answer any leftover burning questions!
Description: Serious incidents related to medical devices must be reported to Swissmedic in Switzerland. The Medical Devices Vigilance (MDV) department is responsible for processing all incoming cases on time. TRICIA can carry out a risk assessment for reports from medical device manufacturers, which supports the MDV department in Swissmedic in assessing the risks of event reports. Internal figures show that the number of reported cases increases every year. With the introduction of the IvDV and the development of the GPx, a further increase in reported cases is also expected over the next few years. Automating the assessment would mean considerably less work for triage. Reports with little relevance can be processed independently, so that they can be better managed by employees therefore increasing organizational effectiveness. In addition, a more homogeneous assessment of cases is possible through the usage of TRICIA. TRICIA is a wonderful case within Swissmedic of what is possible when AI is integrated and thoroughly tested in a meaningful process within the organization.
tests and LDTs
How does regulation differ between the EU and US?
What was changed for all stakeholders?
Areas of particular consideration for manufacturers
Longer term impact of more stringent regulations
- Future outlook on wider patient health and safety
Utilizing Design inputs
How to properly define intended use and device categorization
Literature search
How to reference competitive devices
Clinical evaluation data integration
Group divisions and BEP creation exercise
Have burning questions left over from the last 2 days? Take the opportunity to connect with our speakers and raise those final questions in our ‘Ask the Experts’ panel!
With a bigger focus on bringing innovation back to Europe, which innovation pathways are available?
Comparison of pathways from Europe, US, and beyond
Industry case study: getting an innovative device to market
Lessons learned and alterations for other submissions
Addition of all test data and results determination
Gap assessment to data, deviations, historical testing
Developing a final conclusion
Group division and BER completion
With eyes mainly focusing on the EU MDR, which other wider regulations are there to be aware of which affect the medical device industry?
Sustainability
Data
Digital
How can all stakeholders keep on top of this web of regulatory web?
E&L test requirements and set up
Correct Dose Base Threshold (DBT) for device
Calculation of Analytical Evaluation Threshold (AET)
Method Uncertainty Factor (UF), sensitivity, solvent selection
Applying to intended use and materials
Traditional endpoint tests and critical factors
In-vitro vs In-vivo
Extraction time, temp, and ratios.
Determining gaps from E&L, literature, etc to determine appropriate endpoint test
Group division and BEP completion
Please contact: Kristen Schott – kristen.schott@informa.com If you are interested in participating as a speaker, panelist, moderator or hosting a webinar
As IVDs and Pharmaceuticals become ever more intertwined, how are both industries finding collaboration?
Commonalities in regulatory processes, experiences and pain points
How can both sides support each other?
How does increased collaboration impact diagnostic market availability?
E&L test reports and applying AET for compound analysis
Acceptance criteria for traditional endpoint tests
Common deviations
What to do if you fail
Please contact: Kristen Schott – kristen.schott@informa.com If you are interested in participating as a speaker, panelist, moderator or hosting a webinar
Your EUDAMED challenge as a manufacturer? Achieve a smooth, efficient, compliant and on-time registration of all your devices in 2025. Based on our multi-year expertise of accompanying manufacturers to become live in EUDAMED, we now unveil to you how you will be able to make it happen in a practical "do's and don't" session
- The surprising roadblocks of the "do it yourself" pathway
- Learnings coming from your peers - based on various company size/product portfolio/data quality and IT maturity
- How to trust both your data and your registration processes to be compliant
Evaluating compounds
NOAEL/LOAEL
Cramer categorization
Unknown determination
MOS calculation per ISO 10993-17
Group division and Tox assessment
The beginnings of the BE
Intent of a BE
Definitions and foundations
Standard intent vs regulator interpretation
With devices having to be registered in EUDAMED by Q3 2026, what is the current state of play?
Early experiences with using EUDAMED
Comparison to SWISSDAMED
Is there also a UK equivalent?
Moving towards end of 2026 grace period – what do manufacturers need to do?
Understanding the EHDS Act
Developments
Primary and secondary use
The regulatory scope of the EHDS Act: MDR, IVDR, data legislation and AI Act
Opportunities for innovation with the EHDS Act
Key risks and mitigation
Future proofing compliance and strategy in light of the EHDS
With eyes mainly focusing on the EU MDR, which other wider regulations are there to be aware of which affect the medical device industry?
Sustainability
Data
Digital
How can all stakeholders keep on top of this web of regulatory web?
End to end case study of successful certification
Technical file preparation and submission
Notified body review
Common questions, pain points and lessons
Please contact: Kristen Schott – kristen.schott@informa.com If you are interested in participating as a speaker, panelist, moderator or hosting a webinar
Description: Serious incidents related to medical devices must be reported to Swissmedic in Switzerland. The Medical Devices Vigilance (MDV) department is responsible for processing all incoming cases on time. TRICIA can carry out a risk assessment for reports from medical device manufacturers, which supports the MDV department in Swissmedic in assessing the risks of event reports. Internal figures show that the number of reported cases increases every year. With the introduction of the IvDV and the development of the GPx, a further increase in reported cases is also expected over the next few years. Automating the assessment would mean considerably less work for triage. Reports with little relevance can be processed independently, so that they can be better managed by employees therefore increasing organizational effectiveness. In addition, a more homogeneous assessment of cases is possible through the usage of TRICIA. TRICIA is a wonderful case within Swissmedic of what is possible when AI is integrated and thoroughly tested in a meaningful process within the organization.
With a bigger focus on bringing innovation back to Europe, which innovation pathways are available?
Comparison of pathways from Europe, US, and beyond
Industry case study: getting an innovative device to market
Lessons learned and alterations for other submissions
Your EUDAMED challenge as a manufacturer? Achieve a smooth, efficient, compliant and on-time registration of all your devices in 2025. Based on our multi-year expertise of accompanying manufacturers to become live in EUDAMED, we now unveil to you how you will be able to make it happen in a practical "do's and don't" session
- The surprising roadblocks of the "do it yourself" pathway
- Learnings coming from your peers - based on various company size/product portfolio/data quality and IT maturity
- How to trust both your data and your registration processes to be compliant
With devices having to be registered in EUDAMED by Q3 2026, what is the current state of play?
Early experiences with using EUDAMED
Comparison to SWISSDAMED
Is there also a UK equivalent?
Moving towards end of 2026 grace period – what do manufacturers need to do?
Understanding the EHDS Act
Developments
Primary and secondary use
The regulatory scope of the EHDS Act: MDR, IVDR, data legislation and AI Act
Opportunities for innovation with the EHDS Act
Key risks and mitigation
Future proofing compliance and strategy in light of the EHDS
Following on from yesterday’s morning session, our experts take the time to answer your most asked questions, comments and concerns, as well as answer any leftover burning questions!
The beginnings of the BE
Intent of a BE
Definitions and foundations
Standard intent vs regulator interpretation
Utilizing Design inputs
How to properly define intended use and device categorization
Literature search
How to reference competitive devices
Clinical evaluation data integration
Group divisions and BEP creation exercise
E&L test requirements and set up
Correct Dose Base Threshold (DBT) for device
Calculation of Analytical Evaluation Threshold (AET)
Method Uncertainty Factor (UF), sensitivity, solvent selection
Applying to intended use and materials
Traditional endpoint tests and critical factors
In-vitro vs In-vivo
Extraction time, temp, and ratios.
Determining gaps from E&L, literature, etc to determine appropriate endpoint test
Group division and BEP completion
E&L test reports and applying AET for compound analysis
Acceptance criteria for traditional endpoint tests
Common deviations
What to do if you fail
Addition of all test data and results determination
Gap assessment to data, deviations, historical testing
Developing a final conclusion
Group division and BER completion
Evaluating compounds
NOAEL/LOAEL
Cramer categorization
Unknown determination
MOS calculation per ISO 10993-17
Group division and Tox assessment
As IVDs and Pharmaceuticals become ever more intertwined, how are both industries finding collaboration?
Commonalities in regulatory processes, experiences and pain points
How can both sides support each other?
How does increased collaboration impact diagnostic market availability?
The In Vitro Diagnostic Regulation (IVDR) introduces a significant paradigm shift in the requirements for using biomarker tests within pharmaceutical clinical trials. It is imperative for clinical trial sponsors to comprehend and proactively address these changes. Successfully navigating the complexities of the IVDR is essential to ensure that trial-generated data can robustly support subsequent regulatory submissions. This session is designed to provide illustrative examples of uniquely challenging scenarios and offer potential practical solutions for effectively managing each situation.
- Harmonization of CTA and PSA
- Timing of therapeutic product and CDx approval/co-approval- Oncology and Beyond
- Use of in-house testing exemption to support CDx as needed
- Product Labeling- SmPC and SSP
- Intended purpose/off-label use
- Changes to a CDx Device and Communication with HA
Please contact: Kristen Schott – kristen.schott@informa.com If you are interested in participating as a speaker, panelist, moderator or hosting a webinar
tests and LDTs
How does regulation differ between the EU and US?
What was changed for all stakeholders?
Areas of particular consideration for manufacturers
Longer term impact of more stringent regulations
- Future outlook on wider patient health and safety
Have burning questions left over from the last 2 days? Take the opportunity to connect with our speakers and raise those final questions in our ‘Ask the Experts’ panel!